MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
253.40
+0.15
+0.06%
Pre Market: 253.31 -0.09 -0.04% 08:48 11/12 EST
OPEN
249.78
PREV CLOSE
253.25
HIGH
255.19
LOW
249.44
VOLUME
214
TURNOVER
176.53M
52 WEEK HIGH
261.00
52 WEEK LOW
153.77
MARKET CAP
37.46B
P/E (TTM)
108.47
1D
5D
1M
3M
1Y
5Y
1D
Will New Trial Data Change Biogen (BIIB) Stock Narrative
Simply Wall St · 52m ago
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305
Benzinga · 2d ago
Why Biogen Rose Even Though It Swung To A Loss
Simply Wall St · 2d ago
Biogen And UCB Report Post-Hoc Phase 3 Data For DPZ Indicating Lower Disease Activity In Lupus
NASDAQ · 2d ago
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Biogen (BIIB) and Mettler-Toledo (MTD)
TipRanks · 3d ago
Biogen price target raised to $305 from $245 at Piper Sandler
TipRanks · 3d ago
Weekly Report: what happened at BIIB last week (1102-1106)?
Weekly Report · 3d ago
Biogen Reports Stronger SLE Responses With Investigational Dapirolizumab
TipRanks · 3d ago
More
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.